These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 24510766

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
    Borgert CJ, Mihaich EM, Quill TF, Marty MS, Levine SL, Becker RA.
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
    Juberg DR, Borghoff SJ, Becker RA, Casey W, Hartung T, Holsapple MP, Marty MS, Mihaich EM, Van Der Kraak G, Wade MG, Willett CE, Andersen ME, Borgert CJ, Coady KK, Dourson ML, Fowle JR, Gray LE, Lamb JC, Ortego LS, Schug TT, Toole CM, Zorrilla LM, Kroner OL, Patterson J, Rinckel LA, Jones BR.
    ALTEX; 2014 Apr; 31(1):63-78. PubMed ID: 24114257
    [Abstract] [Full Text] [Related]

  • 9. Assessment of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture, in the EDSP male and female pubertal protocols.
    Stoker TE, Laws SC, Crofton KM, Hedge JM, Ferrell JM, Cooper RL.
    Toxicol Sci; 2004 Mar; 78(1):144-55. PubMed ID: 14999130
    [Abstract] [Full Text] [Related]

  • 10. Analysis of EPA's endocrine screening battery and recommendations for further review.
    Schapaugh AW, McFadden LG, Zorrilla LM, Geter DR, Stuchal LD, Sunger N, Borgert CJ.
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
    [Abstract] [Full Text] [Related]

  • 11. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ.
    Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
    [Abstract] [Full Text] [Related]

  • 12. Effects of altered food intake during pubertal development in male and female wistar rats.
    Laws SC, Stoker TE, Ferrell JM, Hotchkiss MG, Cooper RL.
    Toxicol Sci; 2007 Nov; 100(1):194-202. PubMed ID: 17728285
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
    Paul Friedman K, Papineni S, Marty MS, Yi KD, Goetz AK, Rasoulpour RJ, Kwiatkowski P, Wolf DC, Blacker AM, Peffer RC.
    Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
    Willett CE, Bishop PL, Sullivan KM.
    Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
    [Abstract] [Full Text] [Related]

  • 17. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
    Browne P, Noyes PD, Casey WM, Dix DJ.
    Environ Health Perspect; 2017 Sep 01; 125(9):096001. PubMed ID: 28934726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
    Gray LE, Wilson V, Noriega N, Lambright C, Furr J, Stoker TE, Laws SC, Goldman J, Cooper RL, Foster PM.
    ILAR J; 2004 Sep 01; 45(4):425-37. PubMed ID: 15454681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.